Mesoblast reports positive results from back pain trial

04/24/2013 | Australian Life Scientist

Preliminary results from a midstage trial indicate patients treated with Mesoblast's mesenchymal precursor cells experienced greater pain relief and increased function than those treated with hyaluronic acid alone. Patients who received 6 million cells responded better than those in a higher-dose group. The full results could open the door to a late-stage clinical trial.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA